Ackermans & van Haaren leads EUR 60 million Series B Financing Round for Confo Therapeutics, a Belgian clinical-stage biopharmaceutical company
26 Juillet 2024 - 7:00AM
UK Regulatory
Ackermans & van Haaren leads EUR 60 million Series B Financing
Round for Confo Therapeutics, a Belgian clinical-stage
biopharmaceutical company
Dear shareholder,
Dear Madam, Dear Sir,
please find attached our press release.
Best regards
Ackermans & van Haaren
- Ackermans & van Haaren leads EUR 60 million Series B
Financing Round for Confo Therapeutics (press release 26 July
2024)
Ackermans and Van Haaren... (EU:ACKB)
Graphique Historique de l'Action
De Jan 2025 à Fév 2025
Ackermans and Van Haaren... (EU:ACKB)
Graphique Historique de l'Action
De Fév 2024 à Fév 2025